Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis M Kwong

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Orthopedics|December 15, 2010
Never events and related quality measures following total hip and total knee replacementLouis M Kwong
The American Journal of Managed Care|April 27, 2011
Cost-effectiveness of rivaroxaban after total hip or total knee arthroplastyLouis M Kwong
Orthopedics|June 14, 2012
Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxisLouis M Kwong
The Journal of Arthroplasty|July 2, 2005
Deep vein thrombosis prophylaxis: better living through chemistry--in the affirmativeLouis M Kwong
Vascular Health and Risk Management|August 9, 2011
Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial dataLouis M Kwong
Journal of Surgical Orthopaedic Advances|November 24, 2004
Hip fracture and venous thromboembolism in the elderlyLouis M Kwong
Orthopedics|November 7, 2012
Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxisLouis M Kwong
American Journal of Orthopedics (Belle Mead, N.J.)|December 5, 2002
Selective factor Xa inhibitors: practical guidelines for useLouis M Kwong
Orthopedics|August 26, 2003
Balancing new technology with established techniquesLouis M Kwong
Clinical Pharmacology : Advances and Applications|August 16, 2013
Comparative safety and efficacy of antithrombotics in the management of venous thromboembolism after knee or hip replacement surgery: focus on rivaroxabanLouis M Kwong
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Orthopedics|December 15, 2010
Never events and related quality measures following total hip and total knee replacementLouis M Kwong
The American Journal of Managed Care|April 27, 2011
Cost-effectiveness of rivaroxaban after total hip or total knee arthroplastyLouis M Kwong
Orthopedics|June 14, 2012
Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxisLouis M Kwong
The Journal of Arthroplasty|July 2, 2005
Deep vein thrombosis prophylaxis: better living through chemistry--in the affirmativeLouis M Kwong
Vascular Health and Risk Management|August 9, 2011
Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial dataLouis M Kwong
Journal of Surgical Orthopaedic Advances|November 24, 2004
Hip fracture and venous thromboembolism in the elderlyLouis M Kwong
Orthopedics|November 7, 2012
Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxisLouis M Kwong
American Journal of Orthopedics (Belle Mead, N.J.)|December 5, 2002
Selective factor Xa inhibitors: practical guidelines for useLouis M Kwong
Orthopedics|August 26, 2003
Balancing new technology with established techniquesLouis M Kwong
Clinical Pharmacology : Advances and Applications|August 16, 2013
Comparative safety and efficacy of antithrombotics in the management of venous thromboembolism after knee or hip replacement surgery: focus on rivaroxabanLouis M Kwong
Pageof 3